(RVNC)—Based on all of the information at my disposal, I expect DWP-415 to be, at most, a minor player in the US botulinum-toxin market with a market share comparable to Xeomin. The business model you describe is consistent with such a view, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”